Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.